Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

EC approves BMS’ Opdivo as adjuvant treatment for oesophageal or GEJ cancer patients

pharmatimesAugust 03, 2021

Tag: EC , BMS , Opdivo , GEJ , CRT

PharmaSources Customer Service